Clinical Trial Update: Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating trastuzumab deruxtecan, with or without capecitabine and durvalumab, as neoadjuvant and adjuvant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• IMFINZI (DURVALUMAB)
• Xeloda (capecitabine)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING